Trevi Therapeutics Logo

Trevi Therapeutics

🇺🇸
TRVI
US89532M1018

Trevi Therapeutics is a US-based biopharmaceutical company specializing in the development of innovative therapies for chronic pruritus and neurological conditions. The company focuses on the development of Haduvio to provide essential treatment options for patients with significant unmet medical needs.

Next Quarterly Earnings

Wednesday, November 11, 2026
CW 46
After-Hours
In 76 days

After-hours — typically from around 10:00 p.m. German time (after the US close at 4:00 p.m. New York time).

Quiet period starts on October 14, 2026

Stock Price

Frequently asked questions

When will Trevi Therapeutics report its next quarterly earnings?

Trevi Therapeutics is scheduled to report its next quarterly earnings on 11/11/2026. After-hours — typically from around 10:00 p.m. German time (after the US close at 4:00 p.m. New York time).

When did Trevi Therapeutics last report quarterly earnings?

Trevi Therapeutics last reported quarterly earnings on 8/6/2026 (Q2 2026). Earnings per share (EPS) came in at -0.11 USD.

How often has Trevi Therapeutics beaten expectations?

Trevi Therapeutics has beaten analyst EPS estimates in 3 of its last 5 evaluated quarters (beat rate: 60%).

How do I add the Trevi Therapeutics earnings dates to my calendar?

Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.

All Dates

Q3 2026
Estimate:-$0.13
Actual:
Q2 2026
Missed
Estimate:-$0.11
Actual:-$0.11
Difference:-$0.00
Q1 2026
Missed
Estimate:-$0.08
Actual:-$0.09
Difference:-$0.01
Price reaction (1 day):-2.7 %
Price reaction (7 days):+0.7 %
Q4 2025
Beat
Estimate:-$0.10
Actual:-$0.06
Difference:+$0.04
Price reaction (1 day):-4.5 %
Price reaction (7 days):-4.9 %
Q2 2025
Beat
Estimate:-$0.10
Actual:-$0.08
Difference:+$0.02
Q1 2025
Beat
Estimate:-$0.10
Actual:-$0.09
Difference:+$0.01

Earnings statistics

Estimates vs. results

3/5
Quarters above estimates
60%
Beat rate
+4%
Avg. EPS surprise

Basis: 5 quarters with an analyst estimate and reported EPS.

Past price reactions are not a reliable indicator of future performance.

Company Information

Name
Trevi Therapeutics
Ticker Symbol
TRVI
ISIN
US89532M1018
Country
🇺🇸
USA
Sector